Brian Dolan

👀 from an early subscriber (VC) to @ExitsOutcomes —> exitsandoutcomes.com/pricing/

@MLeshchiner @willahmed Yes, same anatomical site as Apple Watch -- so same process for capturing an ECG: "Left-hand fingers to the right wrist or vice versa on a consumer-grade electronic."

@bddol @willahmed But will they actually implement it ? Bc it would require two points of contact to take the reading similar to Apple or Samsung.

Big announcements this week

@MLeshchiner @willahmed Whoop has kept it quiet, but I reported on this about a month ago. They already have FDA clearance for ECG capture (unannounced) but I'm guessing FDA is about to clear them for irregular heartbeat notification too. Similar to the 2 FDA clearances Apple Watch secured back in 2018.

@willahmed ECGs ?

can't recommend @bddol 's exit & outcomes publication enough - the databases alone are interesting exitsandoutcomes.com/pricing-for-do…

@nealkhosla Verily's Onduo

I'm cackling at the realization I just had that Coca-Cola pays for a diabetes management solution for their employees.

@OliviaWebbC @ExitsOutcomes This was an interesting move for sure. Just to be clear: This was from a newsletter I wrote back in 2021. Pear has since gone bankrupt.

@rikrenard @ExitsOutcomes Now you’re just straight up stealing all my best client advice. Including that they need to subscribe to @ExitsOutcomes

Love @ExitsOutcomes. Among the best healthcare analysts around.

@jacobbrody @ExitsOutcomes Wow. Thanks, Jacob!

@rikrenard @ExitsOutcomes Why not both? Sword did manage to sell to large employers too. Pepsi was their first big-name customer. But their small company strategy helped generate momentum.

The SWORD Health Report is yet another banger by @ExitsOutcomes My fav insight: don't try and sell to the big boyz from day 1 Almost never works. Instead target small customers, get their feedback, and use them for your marketing

Lol wut Via @ExitsOutcomes

@dvansickle @ExitsOutcomes @GregTracy 👀

@chrissyfarr Accolade did get a fair bit of press for that but they didn't get into the details of why they lost the customer. Maybe it was a missed opportunity. twitter.com/bddol/status/1…

@chrissyfarr Accolade losing Comcast. Did that help them though?

Hot take: The first company that has the guts to publish a press release saying they lost a key deal or customer relationship - and explaining why - would get so much press for demonstrating vulnerability that it would ultimately be a huge win

Won't spill all the beans, but you can find the complete report here: #memberful_overlay" target="_blank" rel="nofollow noopener">exitsandoutcomes.com/the-spring-hea… (don't forget to subscribe to @bddol's blog)

The Spring Health Report is another banger by @ExitsOutcomes (@bddol). My top three favorite insights: (1) Sell then build Doesn't matter if this is your 1st product or a feature you'll spend significant time on. Make sure people want to pay (extra)

@jryedinak @agingmedia Congrats!

BIG NEWS - today we announced an agreement to sell @agingmedia to WTWH Media/Mountaingate Capital

@WhelanHealth Yes, but: the Chief Legal Officer at Click, one of the other three buyers, included this line in their bid: "I am not aware of any connection between Click and any insider of the Debtors." Harvest Bio couldn't say the same right? Will those connections cause the judge to nix it?

Quite the turn of events: I speculated last week that the mystery buyer of Pear Therapeutics' core assets was its ex-CEO. The purchase agreement reveals this to be true. McCann, under the name Harvest Bio, seems intent on resurrecting Pear using the following assets --> (1/3)

Who is funding McCann's bid to resurrect Pear? A Boston-based, stealthy investor named T.Rx Capital. The fund T.Rx is using to back up McCann's bid was set up Jan 2023. Former Pear exec Michael Langer appears to be a co-founder and managing director of T.Rx too.

The judge presiding over the bankruptcy court proceedings still needs to sign off on the asset sales --so this isn't a done deal yet. And some have already objected to the sale to McCann -- including the federal government and the South Carolina Department of Corrections. (3/3)